Novartis $372,000 Cancer Drug Hits First Hurdle in Europe

Bookmark
(Bloomberg) -- Novartis AG’s cancer drug Kymriah faced its first setback in Europe as U.K. health authorities made an initial recommendation against paying for the breakthrough therapy to treat a f...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.